degarelix + Goserelin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Aug 13, 2013 → Aug 8, 2016
NCT ID
NCT01964170About degarelix + Goserelin
degarelix + Goserelin is a phase 3 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01964170. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01964170 | Phase 3 | Completed |
Competing Products
20 competing products in Prostate Cancer